Clinical trials: Arsenic Trioxide
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor
Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of arsenic trioxide in treating children who have advanced…
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer
- Trial name
- NCT00024258
- Testing
- arsenic trioxide
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Leukemia, Lymphoma
Arsenic Trioxide in Treating Patients With Recurrent or Refractory Acute Leukemia, Chronic Myeloide Leukemia, Myelodysplasia, Lymphoma, or Myeloma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of arsenic trioxide in treating patients who have…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00003885
- Testing
- arsenic trioxide
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Our Lady of Mercy Medical Center
Acute Promyelocytic Leukemia
Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy
The purpose of this study is to find what effects, good and/or bad, treatment with two drugs has on leukemia. The first medicine is tretinoin (also called all-trans retinoic acid, ATRA, or Vesanoid).
- Trial name
- NCT01404949
- Testing
- Tretinoin and Arsenic Trioxide
- Where
- 12 sites in United States, Canada
- Volunteers
- 17 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
This phase II trial studies how well arsenic trioxide works in treating patients with relapsed or refractory acute myeloid leukemia.
- Conditions
- Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b)
- Trial name
- NCT01835288
- Testing
- arsenic trioxide, laboratory biomarker analysis
- Sponsor
- Stanford University
Lung Cancer
Arsenic Trioxide in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as arsenic trioxide, use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00075426
- Testing
- arsenic trioxide
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- The University of Texas Medical Branch, Galveston
Colorectal Cancer
Arsenic Trioxide, Fluorouracil, and Leucovorin in Treating Patients With Stage IV Colorectal Cancer That Has Relapsed or Not Responded to Treatment
RATIONALE: Drugs used in chemotherapy, such as fluorouracil and leucovorin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00449137
- Testing
- Arsenic trioxide, Fluorouracil, Leucovorin calcium
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Miami
Carcinoma, Hepatocellular
Arsenic Trioxide TACE and Intravenous Administration in Unresectable Hepatocellular Carcinoma
The purpose of this study is to determine whether compared with arsenic trioxide TACE alone, arsenic trioxide TACE and intravenous administration could further prolong the overall survival.
- Trial name
- ACTION (NCT01861912)
- Testing
- Arsenic trioxide TACE, Arsenic trioxide intravenous infusion, lipiodol
- Volunteers
- 258 people
- Sponsor
- Guangdong Provincial People's Hospital
Lymphoma
Arsenic Trioxide in Treating Patients With Relapsed or Refractory Non- Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of arsenic trioxide in treating patients who have…
- Trial name
- NCT00005040
- Testing
- arsenic trioxide
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Skin Basal Cell Carcinoma
Arsenic Trioxide and Itraconazole in Treating Patients With Advanced Basal Cell Cancer
This pilot clinical trial studies how well arsenic trioxide and itraconazole work in treating patients with basal cell cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment.
- Trial name
- NCT02699723
- Testing
- Arsenic Trioxide, Itraconazole, Laboratory Biomarker Analysis
- Sponsor
- Jean Yuh Tang
Acute Promyelocytic Leukemia
New Retinoid Agent Combined With Arsenic Trioxide for Untreated Acute Promyelocytic Leukemia
The safety and efficacy of combining NRX 195183 with arsenic trioxide in treating untreated APL will be assessed.
- Trial name
- NCT00670150
- Testing
- NRX 195183 (retinoid analogue), Arsenic Trioxide
- Where
- United States
- Sponsor
- University of Southern California
Leukemia
Arsenic Trioxide in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Has Not Responded to Previous Treatment
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of arsenic trioxide in treating patients who have chronic…
- Trial name
- NCT00006091
- Testing
- arsenic trioxide
- Sponsor
- M.D. Anderson Cancer Center
Refractory Solid Tumors
Arsenic Trioxide in Refractory Solid Tumors With Rescuable p53 Mutation
This study is an open, prospective, single arm, multi center exploratory basket clinical study. 20 refractory solid tumors patients with rescuable p53 mutation will be enrolled, and the efficacy and safety of arsenic trioxide in…
- Trial name
- NCT04869475
- Testing
- Arsenic trioxide
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Ruijin Hospital
Acute Myeloid Leukemia, P53 Mutation
Decitabine,Cytarabine and Arsenic Trioxide for Acute Myeloid Leukemia With p53 Mutations
This is a prospective,uncontrolled and multi-institution trial.The aim is to identify if using decitabine,cytarabine and ATO as the therapy of acute myeloid leukemia(AML) with p53 mutations has better relapse free survival and…
- Trial name
- NCT03381781
- Testing
- Decitabine, Arsenic Trioxide, Cytarabine
- Where
- 3 sites in China
- Volunteers
- 100 people
- Sponsor
- Li Junmin
Leukemia, Lymphoma
Arsenic Trioxide With or Without Tretinoin in Treating Patients With Hematologic Cancer That Has Not Responded to Previous Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Tretinoin may help hematologic cancer cells develop into normal white blood cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00006220
- Testing
- arsenic trioxide, tretinoin
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Washington University School of Medicine
Extragonadal Germ Cell Tumor, Testicular Germ Cell Tumor
Arsenic Trioxide in Treating Men With Germ Cell Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of arsenic trioxide in treating men who have germ cell…
- Trial name
- NCT00036842
- Testing
- arsenic trioxide
- Where
- 94 sites in United States
- Sponsor
- SWOG Cancer Research Network
Acute Myelogenous Leukemia
Trial of Arsenic Trioxide With Ascorbic Acid in the Treatment of Adult Non-Acute Promyelocytic Leukemia (APL) Acute Myelogenous Leukemia
This clinical research study is for patients with acute myelogenous leukemia (in short AML) that did not respond to previous treatment or unable to receive chemotherapy. Arsenic has been used as a drug for many centuries.
- Trial name
- NCT00184054
- Testing
- Arsenic Trioxide (ATO), Ascorbic Acid
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Southern California
Brain Cancer
Phase I Trial of Arsenic Trioxide and Stereotactic Radiotherapy for Recurrent Malignant Glioma
To investigate the safety of delivering arsenic trioxide (ATO) in combination with stereotactic radiotherapy in recurrent malignant glioma by performing an open label, Phase I dose escalation trial.
- Trial name
- NCT00185861
- Testing
- Arsenic Trioxide, Stereotactic radiosurgery
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Stanford University
Multiple Myeloma and Plasma Cell Neoplasm
Arsenic Trioxide, Thalidomide, Dexamethasone, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma
RATIONALE: Drugs used in chemotherapy, such as arsenic trioxide, dexamethasone, and ascorbic acid, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00227682
- Testing
- ascorbic acid, arsenic trioxide, dexamethasone
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- OHSU Knight Cancer Institute
Arsenic Trioxide, p53 Mutations
Arsenic Trioxide for Structural p53 Mutations
TP53 is the most frequently mutated gene in cancer, but these mutations remain therapeutically non-actionable. Previous study reported arsenic trioxide could rescue structural p53 mutations, endowing p53 mutations with…
- Conditions
- Arsenic Trioxide, p53 Mutations, Refractory Cancer, Intractable Cancer
- Trial name
- NCT04695223
- Testing
- Arsenic Trioxide
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Changzheng Hospital
Acute Promyelocytic Leukemia
Safety, Efficacy, & Pharmacokinetic Study of Tamibarotene to Treat Patients With Relapsed or Refractory APL
This is a Phase II, open-label, non-randomized study to evaluate the safety, efficacy, and pharmacokinetics of tamibarotene in adult patients with relapsed or refractory acute promyelocytic leukemia (APL) following treatment with…
- Trial name
- STAR-1 (NCT00520208)
- Testing
- Tamibarotene
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- CytRx